Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884 · tracked via the Priya Life Science Spain tracker
Phase
Phase 2
Started
2024-08-26
Last updated
2026-09-25

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Talquetamab →Prophylaxis AProphylaxis BProphylaxis CProphylaxis DRamantamig →

Talquetamab: Talquetamab will be administered subcutaneously.

Prophylaxis A: Prophylaxis A will be administered orally.

Prophylaxis B: Prophylaxis B will be administered orally.

Prophylaxis C: Prophylaxis C will be administered orally.

Prophylaxis D: Prophylaxis D will be administered topically.

Ramantamig: Ramantamig will be administered subcutaneously.

Study summary

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Multiple myeloma (MM) according to IMWG diagnostic criteria * Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb) * Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen * Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy * Be willing and able to adhere to the lifestyle restrictions specified in the protocol Exclusion Criteria: * Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients * Stroke, transient ischemic attack, or seizure within 6 months prior to screening * Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary * Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment * A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia

Primary outcome measure(s)

  • Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase — Up to 12 months
    Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.
  • Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase — Up to 12 months
    Severe Dysgeusia is defined as a total WETT score of 10th percentile or below according to the normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.
  • Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase — Up to 12 months
    Time to the first onset of severe dysgeusia is defined as time from the first dose date of talquetamab to the first onset date of severe dysgeusia according to the total WETT score. For participants without severe dysgeusia, time to the first onset will be censored. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.
  • Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase — End of Month 3
    Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 3 becomes total WETT score above 25th percentile at the end of month 3. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 3 becomes total WETT score above 10th percentile at the end of month 3. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, \& umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.
  • Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase — End of Month 7
    Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 7 becomes total WETT score above 25th percentile at the end of month 7. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 7 becomes total WETT score above 10th percentile at the end of month 7. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, \& umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.

Trial sites (38)

FacilityCityRegionStatus
University of California San Francisco San Francisco California Recruiting
Colorado Blood Cancer Institute Denver Colorado Recruiting
Yale University School Of Medicine New Haven Connecticut Recruiting
Icahn School of Medicine at Mt. Sinai New York New York Recruiting
University of Rochester Medical Center Rochester New York Recruiting
Duke University Medical Center Durham North Carolina Recruiting
University Hospitals Cleveland Medical Center Cleveland Ohio Recruiting
Virginia Commonwealth University - Massey Cancer Center Richmond Virginia Recruiting
University of Washington Seattle Washington Recruiting
IDOR - Regional Brasilia Brasília Brazil Recruiting
Fundacao Universidade de Caxias do Sul Caxias do Sul Brazil Recruiting
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer Curitiba Brazil Recruiting
IDOR - Regional Bahia Salvador Brazil Recruiting
IDOR - Regional Sao Paulo São Paulo Brazil Recruiting
Clinica Medica Sao Germano LTDA São Paulo Brazil Recruiting
VUMC Amsterdam Amsterdam Netherlands Recruiting
Albert Schweitzer Ziekenhuis Dordrecht Netherlands Recruiting
Erasmus MC Rotterdam Netherlands Recruiting
Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center San Juan Puerto Rico Recruiting
Seoul National University Hospital Seoul South Korea Recruiting
The Catholic University of Korea Seoul St Mary s Hospital Seoul South Korea Recruiting
Samsung Medical Center Seoul South Korea Recruiting
Hosp. Univ. Germans Trias I Pujol Badalona Spain Recruiting
Hosp Clinic de Barcelona Barcelona Spain Recruiting
Hosp. Univ. Virgen de La Arrixaca El Palmar Spain Recruiting
Hosp. de Jerez de La Frontera Jerez de la Frontera Spain Recruiting
Hosp. Univ. Ramon Y Cajal Madrid Spain Recruiting
Hosp. Univ. 12 de Octubre Madrid Spain Recruiting
Hosp. Quiron Madrid Pozuelo Pozuelo de Alarcón Spain Recruiting
Hosp Clinico Univ de Salamanca Salamanca Spain Recruiting
Belfast City Hospital Belfast United Kingdom Recruiting
Colchester Hospital University NHS Colchester United Kingdom Recruiting
Eastbourne District General Hospital Eastbourne United Kingdom Recruiting
The Clatterbridge Cancer Centre Liverpool United Kingdom Recruiting
University College London Hospitals London United Kingdom Recruiting
Hammersmith Hospital London United Kingdom Recruiting
The Christie NHS Foundation Trust Christie Hospital Manchester United Kingdom Recruiting
Newcastle Freeman Hospital Newcastle upon Tyne United Kingdom Completed
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06500884 on ClinicalTrials.gov ↗ ← All trials in Spain